Quantifying the benefit of nonselective beta-blockers in the prevention of hepatic decompensation: A Bayesian reanalysis of the PREDESCI trial
Authors:
- Ian A. RoweIRIan A. Rowe
- Càndid VillanuevaCVCàndid Villanueva
- Jessica E. ShearerJSJessica E. Shearer
- Ferran TorresFTFerran Torres
- Agustín AlbillosAAAgustín Albillos
- Joan GenescàJGJoan Genescà
- Joan C. Garcia-PaganJGJoan C. Garcia-Pagan
- Dhiraj TripathiDTDhiraj Tripathi
- Peter C. HayesPHPeter C. Hayes
- Jaume BoschJBJaume Bosch
- Juan G. AbraldesJAJuan G. Abraldes
- 13 March 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 78 (2) , 530-539
Abstract
Export Background and aims: Beta-blockers have been studied for the prevention of variceal bleeding and, more recently, for the prevention of all cause decompensation. Some uncertainties regarding the benefit of beta-blockers for the prevention of decompensation remain. Bayesian analyses enhance the interpretation of trials. The purpose of this study was to provide clinically meaningful estimates of both the probability and magnitude of benefit with beta-blocker treatment across a range of patient types. Approach and results: We undertook a Bayesian re-analysis of PREDESCI incorporating three priors (moderate neutral, moderate optimistic, and weak pessimistic). The probability of clinical benefit was assessed considering the prevention of all cause decompensation. Microsimulation analyses were done to determine the magnitude of benefit. In the Bayesian analysis the probability that beta-blockers reduce all cause decompensation was >0.93 for all priors. The Bayesian posterior hazard ratios (HR) for decompensation ranged from 0.50 (optimistic prior, 95% credible interval 0.27-0.93) to 0.70 (neutral prior, 95% credible interval 0.44-1.12). Exploring the benefit of treatment using microsimulation highlights substantial treatment benefit. For the neutral prior derived posterior HR and a 5% annual incidence of decompensation, at 10 years an average of 497 decompensation-free years per 1000 patients were gained with treatment. In contrast, at 10 years 1639 years per 1000 patients were gained from the optimistic prior derived posterior HR and a 10% incidence of decompensation. Conclusions: Beta-blocker treatment is associated with a high probability of clinical benefit. This likely translates to a substantial gain in decompensation-free life years at the population level.Keywords
This publication has 37 references indexed in Scilit:
- Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: A multicentre randomized controlled trialJournal of Hepatology, 2014
- Why representativeness should be avoidedInternational Journal of Epidemiology, 2013
- Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed # †Hepatology, 2009
- Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trialsJournal of Clinical Epidemiology, 2009
- Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated CirrhosisGastroenterology, 2007
- Incorporating Bayesian Ideas into Health-Care EvaluationStatistical Science, 2004
- Methods in health service research: An introduction to bayesian methods in health technology assessmentBMJ, 1999
- Carvedilol, a new nonselective beta-blocker with intrinsic anti-alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosisHepatology, 1999
- Placing Trials in Context Using Bayesian AnalysisJAMA, 1995
- Bayesian Approaches to Randomized TrialsJournal of the Royal Statistical Society Series A: Statistics in Society, 1994